Chemical Properties
Colourless crystals
Uses
Bifunctional DOTA aconjugates to peptides and has become an established strategy for constructing target-specific metal containing agents including targeted MRI contrast agents and diagnostic and ther
apeutic radiopharmaceuticals.
Uses
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is a macrocyclic complexing agent.
- It has been used for radiolabeling of carbon nanotube bioconjugates by chelating 64Cu radioisotope.
- DOTA can be activated with N-hydroxysulfosuccinimidyl for conjugation with monoclonal antibodies in clinical radioimmunotherapy.
- It can form complexes with gadolinium for application as MRI contrast agents.
- Metal complexes of DOTA-peptide conjugates can be used as therapeutic radiopharmaceuticals.
Definition
ChEBI: An azamacrocyle in which four nitrogen atoms at positions 1, 4, 7 and 10 of a twelve-membered ring are each substituted with a carboxymethyl group.
Synthesis
To a three-necked flask, 1,4,7,10-tetraazacyclododecane (100 g, 0.58 mol) and 10 ml of deionized water were added and mixed with stirring. The pH of the reaction system was adjusted to 8.5 by slow dropwise addition of 30% potassium hydroxide solution.Subsequently, chloroacetic acid (263 g, 2.78 mol) was added and the pH was adjusted again to 8.5 using 30% potassium hydroxide solution.The reaction mixture was heated to 80 °C and kept for 24 h, during which time the pH was continually monitored and adjusted to maintain a pH value between 8.5 and 9. After completion of the reaction, it was cooled to room temperature and the pH was adjusted to 2 by adding concentrated hydrochloric acid, at which time a white precipitate was produced. The precipitate was collected by filtration and the filter cake was recrystallized from a mixed water-ethanol solution. The resulting crystals were washed with ethanol and ether in turn, and 183 g of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) crystals were obtained after drying with a yield of 78%.
References
[1] Journal of Labelled Compounds and Radiopharmaceuticals, 2003, vol. 46, # 3, p. 197 - 209
[2] Dalton Transactions, 2016, vol. 45, # 23, p. 9553 - 9564
[3] Patent: WO2014/114664, 2014, A1. Location in patent: Page/Page column 28-29
[4] Patent: WO2015/117911, 2015, A1. Location in patent: Paragraph 0081; 0082; 0083; 0084
[5] Patent: CN104447598, 2017, B. Location in patent: Paragraph 0096; 0098; 0099